A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Recruiting

Phase 2

RP-A501A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Sponsor:

Rocket Pharmaceuticals Inc.

Code:

NCT06092034

Conditions

Danon Disease

Eligibility Criteria

Sex: Male

Age: 8+

Healthy Volunteers: Not accepted

Interventions

RP-A501

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-27. This information was provided to ClinicalTrials.gov by Rocket Pharmaceuticals Inc. on 2025-10-07.